Paltusotine is a small molecule commercialized by Crinetics Pharmaceuticals, with a leading Phase III program in Acromegaly. According to Globaldata, it is involved in 12 clinical trials, of which 7 were completed, 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Paltusotine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Paltusotine is expected to reach an annual total of $71 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Paltusotine hydrochloride (CRN-00808) is under development for the treatment of acromegaly and neuroendocrine tumors, carcinoid syndfrome. The drug candidate is administered through oral route. The drug candidate is a biased nonpeptide acts by targeting somatostatin receptor. The drug candidate was under development for age-related macular degeneration (AMD) and diabetic retinopathy.
Crinetics Pharmaceuticals Overview
Crinetics Pharmaceuticals (Crinetics) is a pharmaceutical company. It developes of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products portfolio comprises paltusotine (Oral SST2 agonist); CRN04777 (SST5 agonist); and CRN04894 (ACTH agonist). It provides somatostatin agonists for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia. The company provides endocrine drug discovery and development through collaboration with healthcare and research institutes. Crinetics is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.1 million in FY2020. The operating loss of the company was US$107.7 million in FY2021, compared to an operating loss of US$75 million in FY2020. The net loss of the company was US$107.6 million in FY2021, compared to a net loss of US$73.8 million in FY2020. The company reported revenues of US$0.5 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.
For a complete picture of Paltusotine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.